Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment
Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment
复制标题
DOI：
10.1182/blood-2016-03-679209
复制
发表时间：
2016-07-28
期刊：
影响因子：
20.3
通讯作者：
Durum, Scott K.
中科院分区：
文献类型：
--
作者：
Cramer, Sarah D.;Aplan, Peter D.;Durum, Scott K.
对小儿急性淋巴细胞白血病（ALL）病理学的了解增加，导致患者生存率的显着改善。然而，仍然需要开发靶向治疗以降低化疗强度并治疗复发患者。白细胞介素-7受体α（IL-7 R α）信号通路是主要的治疗靶点，因为这些通路在T细胞ALL和B细胞前体ALL中都存在遗传畸变。IL-7 R α信号通路的治疗靶向可能导致患者亚组的结局改善。
Increased understanding of pediatric acute lymphoblastic leukemia (ALL) pathobiology has led to dramatic improvements in patient survival. However, there is still a needto developtargeted therapies toenable reduced chemotherapy intensity and to treat relapsed patients. The interleukin-7 receptor alpha ( IL-7R alpha) signaling pathways areprime therapeutic targetsbecause these pathways harbor genetic aberrations in both T-cell ALL and B-cell precursor ALL. Therapeutic targeting of the IL-7R alpha signaling pathways may lead to improved outcomes in a subset of patients.